An observational study in Atopic Dermatitis, sponsored by Sanofi. Active, not recruiting at 61 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 4th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2025, is one of 15 observational ones, reaches primary completion later than 5 of the 15 other live ones, and was the 39th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:
Sanofi · Sites in Qatar, Saudi Arabia, United Arab Emirates
Ages 12+
Sanofi · Sites in United States, Canada, China and 6 more countries
Ages 12+
Sanofi · Sites in Italy
Ages 6 mo–17 yrs
Sanofi
Ages 12+
Sanofi
Ages 18+
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 8
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 150 across 284 observational studies indexed under Dermatitis, Atopic.
Median enrollment 112 across the 28 interventional studies, 266 across the 15 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
6 of the studies in Dermatitis, Atopic by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT06837454SanofiFrench Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | 2027-05-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies in Dermatitis, Atopic by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.
Patients participating in this study will be more than equal to (≥) 18 years old, managed in France for moderate to severe AD, and who are either eligible to systemic treatment or currently under systemic treatment, in realworldsettings within the inclusion period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with moderate to severe AD according to the Investigator's judgment and
Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT) more than or equal to (≥) 7 and/or use topical (TCS) more than (>) 90 gram (g)/month and/or TCS are not advisable.
or
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study plans to collect information on patients during visits according to clinical practice. Enrolled patients will receive AD treatment of marketed drugs prescribed by the specialty physician. No investigational drug will be given for the purpose of this study.
Previous and Current Treatments for Atopic Dermatitis (AD)
List of previous and current treatments for AD based on physician-reported data will be assessed.
Time frame: Baseline, month 6 and month 12
Atopic Comorbidities: Previous and Current Therapeutic Management
Description of previous and current therapeutic management of atopic comorbidities over time based on physician-reported data will be assessed.
Time frame: Baseline, month 6 and month 12
Change from Baseline in Drug Survival for Systemic Treatments for AD by Name and Dose
Drug survival is defined as the time from the start of treatment to the end or discontinuation of treatment with no changes. If a patient has multiple drug survival events for the same treatment, the longest drug survival will be used in the data summarization. The drug survival will be illustrated using a Kaplan-Meier plot.
Time frame: Baseline, month 6 and month 12
Compliance for AD Treatments
Compliance for AD treatments will be assessed by the physician.
Time frame: Baseline, month 6 and month 12
Demographic Characteristics of Participants
Demographics characteristics including birth date, gender, and socio-professional category, height, weight, phototype (type I to type VI according to Fitzpatrick's classification).
Time frame: Baseline
Medical History and AD history
Medical history will be summarized using the Medical Dictionary for Regulatory Activities (MedDRA) codes of System Organ Class (SOC) and Preferred Terms (PT).
Time frame: Baseline
Change from Baseline in AD Severity
Change from baseline in AD severity assessed through physician-reported persistence with prescribed therapy.
Time frame: Baseline, month 6 and month 12
Atopic Comorbidities
Description of the presence, evolution, and therapeutic management of atopic comorbidities over time based on physician-reported data.
Time frame: Baseline, month 6 and month 12
Non-atopic Comorbidities
Description of the presence, evolution, and therapeutic management of non-atopic comorbidities over time based on physician-reported data.
Time frame: Baseline, month 6 and month 12
Use of Psychoactive Substances
Description of the use of psychoactive substances over time based on patient-reported data.
Time frame: Baseline, month 6 and month 12
Change from Baseline in Itch Assessment
Itch assessment (Worst-Itch Numeric Rating Scale, WI-NRS) will be rated from 0 to 10 on average during the past 7 days, completed by the observing physician after questioning of patient; 0 = no itch and 10 = the worst imaginable itch.
Time frame: Baseline, month 6 and month 12
Change from Baseline in Sleep Disturbance NRS
NRS sleep disturbance will be rated from 0 to 10 on average during the past 7 days, completed by the observing physician after questioning of patient; 0 = "sleep not disturbed at all" (best possible sleep) and 10 = "sleep extremely disturbed (worst possible sleep)".
Time frame: Baseline, month 6 and month 12
Change from Baseline in Skin Pain NRS
Skin pain NRS will be rated from 0 to 10 on average during the past 7 days prior to the visit. On a scale of 0 to 10, with 0 being 'no skin pain at all' and 10 being 'the worst imaginable skin pain'.
Time frame: Baseline, month 6 and month 12
Change from Baseline in AD Disease Control Using the Atopic Dermatitis Control Tool (ADCT)
ADCT is a questionnaire to assess patient-self-perceived control of their AD with a total score from 0 to 24; higher scores indicate lower AD control.
Time frame: Baseline, month 6 and month 12
Change from Baseline in Dermatology Life Quality Index (DLQI)
DLQI is a 10-item questionnaire to measure dermatology specific quality of life (QoL). DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than 10 indicates that the patient's life is being severely affected by their skin disease.
Time frame: Baseline, month 6 and month 12
Change from Baseline in Psychological Comorbidities Assessed using Hospital Anxiety and Depression Scale (HADS)
The HADS is a 14-item patient-reported outcomes measure used to assess states of anxiety and depression over the past week. It is comprised of 7 items assessing anxiety and depression respectively. A Total score is out of 42 (21 per subscale). Higher scores indicate greater levels of anxiety and/or depression.
Time frame: Baseline, month 6 and month 12
Cumulative Life Course Impairment (CLCI) - for Physicians in Hospital Centers
CLCI-r instrument determines retrospectively which changes and effects the patients have already experienced due to the disease over their entire disease course. CLCI-p determines the patient's current situation and thus identifies risk areas in which the patient could experience burdens in the future.
Time frame: Baseline, month 6 and month 12
Change from Baseline in Patient's Treatment Satisfaction Score Using the Patient Global Assessment of Treatment Effect (PGATE)
Patient's treatment satisfaction score will be assessed using Patient Global Assessment of Treatment Effect (PGATE). PGATE is an assessment tool used to rate the treatment effect of the medication on atopic dermatitis (AD), with scores ranging from 0 to 4 (0 = poor; 1 = fair; 2 = good; 3 = very good; 4 = excellent), i.e., higher score indicated higher treatment effect.
Time frame: Baseline, month 6 and month 12
Evolution of Atopic Comorbidities
Evolution of atopic comorbidities over time, assessed through physician-reported status, occurrence of new diagnoses and persistence of existing conditions.
Time frame: Baseline, month 6 and month 12
Management of AD from First Diagnosis
History of healthcare pathway of participant related to AD will be assessed by the physician (if participant had appointment with other healthcare provider for AD).
Time frame: Baseline, month 6 and month 12
Therapeutic Education
History of healthcare pathway of participant related to AD will be assessed by the physician (if participant received therapeutic education).
Time frame: Baseline, month 6 and month 12
Cost of Emollients and Hygiene Products
Cost of emollients, hygiene products etc. during the last month of the study visit will be assessed.
Time frame: At month 12
Sick Leaves Related to AD
Number of sick leaves participant has taken related to AD since the last visit or over the last 6 months.
Time frame: Baseline, month 6 and month 12
Hospitalization with Overnight Stay Related to AD
Overnight hospitalization related to AD since the last visit or over the last 6 months.
Time frame: Baseline, month 6 and month 12
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for May 2027, 27 months after the start.
Of 74 industry-sponsored observational studies under Dermatitis, Atopic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 84. This study's planned 27 months is below that.
Counting every sponsor, half of 172 studies reached it within 47 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.